Meeting
2022 ASCO Genitourinary Cancers Symposium
Gemcitabine and carboplatin versus gemcitabine and paclitaxel chemotherapy in cisplatin ineligible advanced-stage urothelial cancers: A prospective randomized control study.
Authors
Parmod Kumar
All India Institute of Medical Sciences, Rishikesh, India
Parmod Kumar , Amit Sehrawat , Deepak sundriyal , Pankaj Sharma , Ankur Mittal , Manoj Kumar Gupta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
CTRI/2020/02/023402
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 500)
DOI
10.1200/JCO.2022.40.6_suppl.500
Abstract #
500
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
First Author: Thomas Powles
Poster
2016 Genitourinary Cancers Symposium
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
First Author: Robert J. Jones
Poster
2016 Genitourinary Cancers Symposium
Sequential chemotherapy with gemcitabine+carboplatin followed by gemcitabine+carboplatin+docetaxel for advanced upper-tract urothelial cancer.
First Author: Takahiro Yoneyama
Poster
2015 Genitourinary Cancers Symposium
Carboplatin-based sequential chemotherapy for aged patients with advanced bladder cancer.
First Author: Takahiro Yoneyama